Piper Sandler Maintains Overweight on Insulet, Raises Price Target to $285
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on Insulet (NASDAQ:PODD) and raised the price target from $230 to $285.
September 17, 2024 | 11:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has increased its price target for Insulet from $230 to $285, maintaining an Overweight rating. This suggests confidence in Insulet's future performance.
The increase in price target from $230 to $285 by Piper Sandler indicates a positive outlook on Insulet's future performance. The Overweight rating suggests that the analyst expects the stock to outperform the market. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100